Author: Willem van Lawick

Dutch biotechnology company Mucosis B.V. announced today that Dr. Barry Buckland was elected to its Supervisory Board. Dr Buckland brings extensive experience in vaccine design and development.

From October 13th till October 15th the very first TOP Course Thoracic Transplantation was held in Berlin. The TOP Course is an Official Course of the ESOT Educational Program. Five specialized and experienced (cardio)thoracic surgeons and one anestesiologist were leading the course. Twelve participants from different European countries (Belgium, Germany, Russia, Denmark, Sweden and Poland)… Continue reading Organ Assist was present at the very first TOP Course for thoracic transplantation in Berlin.

Leiden, October 13, 2010 – Prosensa, the Dutch biopharmaceutical company focusing on RNA modulating therapeutics, has announced that it received a £7.5m milestone payment from GlaxoSmithKline (GSK) as a result of achieving a data milestone in its Phase IIa open label extension trial of GSK2402968 (PRO051), being developed to treat Duchenne Muscular Dystrophy (DMD) under… Continue reading Prosensa receives £7.5m milestone payment as part of its program with GlaxoSmithKline in Duchenne Muscular Dystrophy

Dutch biotechnology company Mucosis B.V. announced today that it has entered into a collaboration agreement with the global health nonprofit organization PATH to pursue the use of the company’s Mimopath™ technology in oral vaccines to prevent and treat severe diarrhea.

Dutch biotechnology company Mucosis B.V. announced today that John Lambert was elected as member and chair of its Supervisory Board. Having held various key positions at pharmaceutical and biotech companies in both the United States and Europe, Mr. Lambert brings exceptional vaccine industry experience to Mucosis.